Here are four things to know about the deal.
1. Pfizer is developing the experimental drug to treat a cognitive impairment associated with schizophrenia. The drug aims to connect signals in the central nervous system previously disrupted by the mental disorder.
2. Through the deal, Biogen would give Pfizer $75 million in an upfront payment, along with up to $515 million in development and commercialization milestone payments. Biogen also agreed to give Pfizer royalties for the drug.
3. The deal, expected to close in the second quarter of this year, marks Biogen’s entrance into the neuropsychiatry market.
4. Biogen will start midstage tests of the drug in the second half of 2018.
More articles on supply chain:
Teva shutters offices in New York City, Washington D.C., as part of cost cutting plan
AbbVie, Biogen pull multiple sclerosis drug from the market citing safety concerns: 4 things to know
Amazon ‘poaches’ 20 jobs from CVS, Express Scripts, UnitedHealth: 6 things to know
